Idexx Laboratories (IDXX) 159.08 $IDXX
Digital Pathology Systems - Global Strategic Business Report 2015-2020: Fast Paced Adoption in Cancer and Other Chronic Diseases
M2 - Thu Feb 12, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdhg3v/digital_pathology) has announced the addition of the "Digital Pathology Systems - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Digital Pathology Systems in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 50 companies including many key and niche players such as: - 3DHISTECH Ltd. - AccelPath, Inc. - Apollo PACS, Inc. - Carl Zeiss AG - Corista LLC - Definiens AG - DigiPath Inc. - Flagship Biosciences, LLC - Koninklijke Philips Electronics N.V. - Leica Microsystems GmbH - MikroScan Technologies, Inc. - Olympus America, Inc. - Omnyx, LLC - Pixcelldata Ltd. - Ventana Medical Systems, Inc. - VMscope GmbH Key Topics Covered: 1. INDUSTRY OVERVIEW - A Prelude - Impact of Economic Recession in Retrospect & the Road Ahead - Market Outlook - Developed Markets to Maintain their Dominance - Digital Pathology Systems See Fast Paced Growth in Emerging Nations - Analytics: A Fast Growing Segment - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - The Future in Retrospect 2. MARKET DRIVERS, TRENDS & ISSUES - The Need for Automation in Tissue Analysis - Workflow Efficiencies: A Key Market Driver for Digital Pathology Systems - Scarcity of Pathologists & Excess Workload on Pathology Labs Drives Demand for Digital Systems - Need for Early Diagnosis Puts Focus on Digital Pathology - Clinical Research Continues to be Core Vertical for Digital Pathology - Technological Advances Ease Issues in Digital Pathology Adoption - Possibilities Ahead in Digital Pathology - Digital Pathology Systems Continue to Widen their Scope - Digital Pathology Systems See Fast Paced Adoption in Cancer and Other Chronic Diseases - Move towards Hosted Technology: The New Fad - Digital Pathology as a Service Eludes Cost-based Issues - Telepathology Expected to Pave Way for Pathology Outsourcing to Developing Nations - Rising Emphasis on Lab Automation Extends Opportunity for Digital Pathology - Rising Penetration of Personalized Medicine Bodes Well for Digital Pathology - Increased Focus on Companion Diagnostics to Benefit the Market - Improving Healthcare & Research Expenditures Turbo Charge Digital Pathology - Burgeoning Global Population: A Strong Business Case for Market Growth - Aging Population: A Key Opportunity Indicator - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - High Costs - Workflow Integration with Other Related Functions - Other Issues 3. COMPETITION - Leica Dominates the Market - Consolidation Rife in the Digital Pathology Space 4. PRODUCT OVERVIEW - An Introduction to Pathology - Digital Pathology: Computer-Enabled Pathology Process - Digital Pathology System: Components - Slide Scanners - Analytics - Storage - Communication - Applications - Remote Reviewing - Digital-Assisted Mathematical Analysis - Data Storage - Telepathology - Static Telepathology - Dynamic Telepathology - Hybrid Telepathology - Bio-banking - Multinational Integration - Tissue Microarray Analysis - A Review of Information Archival and Retrieval in Digital Pathology - Storage and Interoperability - Location and Internal Communication - Systems and Data Reliability - Image Life-Cycle Management - IT infrastructure and Management Costs - Factors Affecting Information Archival - Digital Pathology Management Systems - Benefits of Digital Pathology Systems - Easier Analysis and Archival & Retrieval of Digital Images - Access to Digital Slide Images Anytime Anywhere 5. PRODUCT INTRODUCTIONS/INNOVATIONS - Philips Obtains CE Mark Approval for Diagnostic Use of its Philips Digital Pathology Solution - Mikroscan Technologies Unveils Mikroscan L6 and the Mikroscan MC2 Telepathology Systems - Royal Philips Receives FDA 510(k) Clearance for Her2/neu IHC Digital Manual Read Product - Ventana Medical Systems Launches iScan HT Slide Scanner - Ventana Obtains FDA 510(k) Clearance for VENTANA Companion Algorithm Ki-67 (30-9) Image Analysis Solution 6. RECENT INDUSTRY ACTIVITY - Visiopharm Begins Operations in Benelux - Pixcelldata Selects Edge Solutions as its US Partner - CellNetix Pathology and Laboratories Merges with Highline Pathology Associates - Definiens Teams Up with Clarient Diagnostic Services - Pixcelldata Signs Partnership Deal with eX-Path - Pixcelldata Inks Partnership Agreement with Basys Data - IDEXX Laboratories Inks Collaboration Agreement with Royal Philips - Ventana Medical Systems and EMC Join Hands - XIFIN Acquires PathCentral - Kanteron Systems Signs Joint Selling & Marketing Agreement with DigiPath - DigiPath Inks New Agreement with Personalized Diagnostic - Dako to Launch Clinical Image Analysis for Digital Pathology - Ventana Medical Systems Inks Global Agreement with Barco - MEDITE Teams Up with UNIC Technologies - Leica Biosystems Takes Over Aperio Technologies - Carl Zeiss MicroImaging and Olympus America Sign Licensing Agreement - Aperio Technologies and Dell Enter into Strategic Collaboration - AccelPath Acquires DigiPath Solutions - Leica Microsystems and Indica Labs Sign Agreement - Omnyx Receives CE Mark in Europe - Erasmus MC Selects Philips to Adopt Digital Pathology System 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 50 (including Divisions/Subsidiaries 54) - The United States (27) - Canada (4) - Japan (2) - Europe (19) - Germany (6) - The United Kingdom (1) - Spain (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/vd..._pathology
PHG: 28.93 (-0.07), IDXX: 159.08 (+1.72)
Idexx Labs (IDXX) Downgraded From Buy to Hold
at The Street - Tue Feb 03, 11:20AM CST
Idexx Labs (IDXX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
IDXX: 159.08 (+1.72)
Shares of IDXX Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:14AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 4 months, Idexx Laboratories has returned 27.23% as of today's recent price of $155.87.
IDXX: 159.08 (+1.72)
IDEXX Tops Q4 Earnings, Lags Revenues; Tweaks 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
IDEXX Laboratories, Inc. (IDXX), reported adjusted earnings per share (EPS) of 95 cents in the fourth quarter of 2014.
HNSN: 1.05 (+0.02), EW: 134.23 (+1.89), IDXX: 159.08 (+1.72), HOLX: 30.46 (+0.21)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 6:44PM CST
IDXX: 159.08 (+1.72)
Idexx guides '15 sales below
at Investor's Business Daily - Fri Jan 30, 5:37PM CST
The veterinary diagnostic and health care company's Q4 EPS rose 16% to 95 cents, beating views by 15 cents. Revenue dipped 0.6% to $351.9 mil, under views for $373.2 mil. Idexx Laboratories (IDXX) sees full-year EPS of $4.33-$4.43 with revenue of...
IDXX: 159.08 (+1.72)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 4:35PM CST
TCK: 15.37 (+0.38), STV: 3.60 (+0.03), GNR: 46.15 (+0.69), KEYS: 36.49 (+0.27), EDU: 18.79 (+0.01), N: 101.72 (+3.38), MBT: 10.36 (+0.62), IDXX: 159.08 (+1.72), ROVI: 24.21 (+0.55), GSG: 21.18 (+0.43)
Hold Your Horses, IDEXX Laboratories, Inc. Earnings Are Better Than They Appear
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 30, 3:35PM CST
IDEXX Laboratories ' earnings per share fell 34% year over year in the fourth quarter, but the veterinary test specialist's numbers require some adjustments. Starting this year, IDEXX will sell its diagnostic products directly to U.S....
IDXX: 159.08 (+1.72)
Idexx updates guidance Q4 results
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 8:40AM CST
IDXX: 159.08 (+1.72)
IDEXX Laboratories (IDXX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Jan 30, 7:25AM CST
IDXX: 159.08 (+1.72)
Idexx tops 4Q profit forecasts
Automated Insights - Fri Jan 30, 6:40AM CST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter profit of $26 million.
IDXX: 159.08 (+1.72)
IDEXX Laboratories beats by $0.15, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 6:03AM CST
IDXX: 159.08 (+1.72)
IDEXX Laboratories Announces Fourth Quarter Results
PR Newswire - Fri Jan 30, 6:00AM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2014 of $352 million. Continued strong normalized organic revenue growth1,2 was offset in the quarter by a one-time $25 million reduction in US channel inventory related to the Company's transition to a fully-direct CAG Diagnostics sales strategy in the US and foreign exchange impacts from a stronger US dollar, resulting in a 1% reported revenue decline. Adjusting for one-time channel inventory reductions, the effect of foreign exchange rate changes, and revenue attributable to acquisitions, normalized organic revenue growth for the quarter was 9%, and 10% for the full year, supported by 11.5% normalized organic growth in CAG Diagnostics recurring revenues in Q4 and 11.4% for the full year.
IDXX: 159.08 (+1.72)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 4:30PM CST
CNX: 33.60 (+0.87), GHM: 22.84 (+0.04), SPG: 193.11 (-1.61), PCAR: 64.22 (+0.98), NS: 61.94 (-0.06), LM: 57.84 (-0.25), BZH: 17.13 (-0.04), NWL: 39.57 (+0.32), MAT: 27.61 (+0.17), MOG.A: 74.61 (+1.47), WY: 35.52 (-0.04), AVY: 53.79 (+0.14), ABBV: 58.05 (+1.00), HMC: 32.87 (+0.14), MA: 87.14 (-0.38), BERY: 34.98 (+0.03), KCG: 12.64 (-0.08), TYC: 43.19 (+0.27), INGR: 82.82 (+0.59), IMGN: 7.19 (unch), MAN: 77.51 (+0.77), IR: 67.69 (+0.06), XRX: 13.77 (+0.20), LLY: 70.56 (+0.03), TSN: 40.70 (-0.09), MO: 54.76 (-0.78), LEA: 108.70 (-0.73), NVO: 43.76 (+0.61), OFG: 17.19 (-0.31), MOSY: 2.10 (+0.02), IDXX: 159.08 (+1.72), SAIA: 45.59 (+0.98), CVX: 112.78 (+1.92), BEN: 53.91 (+0.23), MGIC: 6.40 (+0.03)
Idexx: The Growth Is There, The Moat Is There, But The Value Probably Isn't
Investing Doc - at Seeking Alpha - Tue Jan 27, 1:41PM CST
IDXX: 159.08 (+1.72), WOOF: 52.74 (-0.27), PETM: 82.70 (+0.03)
Idexx Laboratories Has Returned 34.9% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Tue Jan 27, 9:50AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 months, Idexx Laboratories has returned 34.93% as of today's recent price of $165.31.
IDXX: 159.08 (+1.72)
Meridian Bioscience: In-line Earnings, Revenue Beat in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:10AM CST
Diagnostic test-kit maker Meridian Bioscience, Inc. (VIVO) reported first-quarter fiscal 2015 (ended Dec 31, 2014) EPS of 19 cents, up 6% on a year-over-year basis and inline with the Zacks Consensus Estimate
VIVO: 19.15 (+0.16), AXDX: 22.86 (-0.33), IDXX: 159.08 (+1.72), VRML: 2.08 (+0.12)
IDEXX Laboratories to Release 2014 Fourth Quarter and Full-Year Financial Results
PR Newswire - Fri Jan 23, 2:32PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 fourth quarter and full-year financial results for Friday, January 30, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 159.08 (+1.72)
IDEXX's SDMA Test: Key to Kidney Disease Diagnosis in Pets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 12:30PM CST
IDEXX's (IDXX) SDMA test is a new renal biomarker that can detect the outset of kidney disease in cats and dogs, months or even years before traditional procedures can spot the same.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), IDXX: 159.08 (+1.72), SURG: 4.44 (-0.02)
Can Covidien (COV) Keep Its Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 10:30AM CST
The combination of Covidien's (COV) Zacks Rank #3 (Hold) and ESP of 2.91% makes us confident of an earnings beat this season.
ALGN: 56.90 (-0.34), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), IDXX: 159.08 (+1.72)
Digital Pathology Systems - Global Strategic Business Report 2015-2020: Fast Paced Adoption in Cancer and Other Chronic Diseases
M2 - Thu Feb 12, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdhg3v/digital_pathology) has announced the addition of the "Digital Pathology Systems - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Digital Pathology Systems in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 50 companies including many key and niche players such as: - 3DHISTECH Ltd. - AccelPath, Inc. - Apollo PACS, Inc. - Carl Zeiss AG - Corista LLC - Definiens AG - DigiPath Inc. - Flagship Biosciences, LLC - Koninklijke Philips Electronics N.V. - Leica Microsystems GmbH - MikroScan Technologies, Inc. - Olympus America, Inc. - Omnyx, LLC - Pixcelldata Ltd. - Ventana Medical Systems, Inc. - VMscope GmbH Key Topics Covered: 1. INDUSTRY OVERVIEW - A Prelude - Impact of Economic Recession in Retrospect & the Road Ahead - Market Outlook - Developed Markets to Maintain their Dominance - Digital Pathology Systems See Fast Paced Growth in Emerging Nations - Analytics: A Fast Growing Segment - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - The Future in Retrospect 2. MARKET DRIVERS, TRENDS & ISSUES - The Need for Automation in Tissue Analysis - Workflow Efficiencies: A Key Market Driver for Digital Pathology Systems - Scarcity of Pathologists & Excess Workload on Pathology Labs Drives Demand for Digital Systems - Need for Early Diagnosis Puts Focus on Digital Pathology - Clinical Research Continues to be Core Vertical for Digital Pathology - Technological Advances Ease Issues in Digital Pathology Adoption - Possibilities Ahead in Digital Pathology - Digital Pathology Systems Continue to Widen their Scope - Digital Pathology Systems See Fast Paced Adoption in Cancer and Other Chronic Diseases - Move towards Hosted Technology: The New Fad - Digital Pathology as a Service Eludes Cost-based Issues - Telepathology Expected to Pave Way for Pathology Outsourcing to Developing Nations - Rising Emphasis on Lab Automation Extends Opportunity for Digital Pathology - Rising Penetration of Personalized Medicine Bodes Well for Digital Pathology - Increased Focus on Companion Diagnostics to Benefit the Market - Improving Healthcare & Research Expenditures Turbo Charge Digital Pathology - Burgeoning Global Population: A Strong Business Case for Market Growth - Aging Population: A Key Opportunity Indicator - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - High Costs - Workflow Integration with Other Related Functions - Other Issues 3. COMPETITION - Leica Dominates the Market - Consolidation Rife in the Digital Pathology Space 4. PRODUCT OVERVIEW - An Introduction to Pathology - Digital Pathology: Computer-Enabled Pathology Process - Digital Pathology System: Components - Slide Scanners - Analytics - Storage - Communication - Applications - Remote Reviewing - Digital-Assisted Mathematical Analysis - Data Storage - Telepathology - Static Telepathology - Dynamic Telepathology - Hybrid Telepathology - Bio-banking - Multinational Integration - Tissue Microarray Analysis - A Review of Information Archival and Retrieval in Digital Pathology - Storage and Interoperability - Location and Internal Communication - Systems and Data Reliability - Image Life-Cycle Management - IT infrastructure and Management Costs - Factors Affecting Information Archival - Digital Pathology Management Systems - Benefits of Digital Pathology Systems - Easier Analysis and Archival & Retrieval of Digital Images - Access to Digital Slide Images Anytime Anywhere 5. PRODUCT INTRODUCTIONS/INNOVATIONS - Philips Obtains CE Mark Approval for Diagnostic Use of its Philips Digital Pathology Solution - Mikroscan Technologies Unveils Mikroscan L6 and the Mikroscan MC2 Telepathology Systems - Royal Philips Receives FDA 510(k) Clearance for Her2/neu IHC Digital Manual Read Product - Ventana Medical Systems Launches iScan HT Slide Scanner - Ventana Obtains FDA 510(k) Clearance for VENTANA Companion Algorithm Ki-67 (30-9) Image Analysis Solution 6. RECENT INDUSTRY ACTIVITY - Visiopharm Begins Operations in Benelux - Pixcelldata Selects Edge Solutions as its US Partner - CellNetix Pathology and Laboratories Merges with Highline Pathology Associates - Definiens Teams Up with Clarient Diagnostic Services - Pixcelldata Signs Partnership Deal with eX-Path - Pixcelldata Inks Partnership Agreement with Basys Data - IDEXX Laboratories Inks Collaboration Agreement with Royal Philips - Ventana Medical Systems and EMC Join Hands - XIFIN Acquires PathCentral - Kanteron Systems Signs Joint Selling & Marketing Agreement with DigiPath - DigiPath Inks New Agreement with Personalized Diagnostic - Dako to Launch Clinical Image Analysis for Digital Pathology - Ventana Medical Systems Inks Global Agreement with Barco - MEDITE Teams Up with UNIC Technologies - Leica Biosystems Takes Over Aperio Technologies - Carl Zeiss MicroImaging and Olympus America Sign Licensing Agreement - Aperio Technologies and Dell Enter into Strategic Collaboration - AccelPath Acquires DigiPath Solutions - Leica Microsystems and Indica Labs Sign Agreement - Omnyx Receives CE Mark in Europe - Erasmus MC Selects Philips to Adopt Digital Pathology System 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 50 (including Divisions/Subsidiaries 54) - The United States (27) - Canada (4) - Japan (2) - Europe (19) - Germany (6) - The United Kingdom (1) - Spain (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/vd..._pathology
PHG: 28.93 (-0.07), IDXX: 159.08 (+1.72)
Idexx Labs (IDXX) Downgraded From Buy to Hold
at The Street - Tue Feb 03, 11:20AM CST
Idexx Labs (IDXX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
IDXX: 159.08 (+1.72)
Shares of IDXX Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:14AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 4 months, Idexx Laboratories has returned 27.23% as of today's recent price of $155.87.
IDXX: 159.08 (+1.72)
IDEXX Tops Q4 Earnings, Lags Revenues; Tweaks 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
IDEXX Laboratories, Inc. (IDXX), reported adjusted earnings per share (EPS) of 95 cents in the fourth quarter of 2014.
HNSN: 1.05 (+0.02), EW: 134.23 (+1.89), IDXX: 159.08 (+1.72), HOLX: 30.46 (+0.21)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 6:44PM CST
IDXX: 159.08 (+1.72)
Idexx guides '15 sales below
at Investor's Business Daily - Fri Jan 30, 5:37PM CST
The veterinary diagnostic and health care company's Q4 EPS rose 16% to 95 cents, beating views by 15 cents. Revenue dipped 0.6% to $351.9 mil, under views for $373.2 mil. Idexx Laboratories (IDXX) sees full-year EPS of $4.33-$4.43 with revenue of...
IDXX: 159.08 (+1.72)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 4:35PM CST
TCK: 15.37 (+0.38), STV: 3.60 (+0.03), GNR: 46.15 (+0.69), KEYS: 36.49 (+0.27), EDU: 18.79 (+0.01), N: 101.72 (+3.38), MBT: 10.36 (+0.62), IDXX: 159.08 (+1.72), ROVI: 24.21 (+0.55), GSG: 21.18 (+0.43)
Hold Your Horses, IDEXX Laboratories, Inc. Earnings Are Better Than They Appear
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 30, 3:35PM CST
IDEXX Laboratories ' earnings per share fell 34% year over year in the fourth quarter, but the veterinary test specialist's numbers require some adjustments. Starting this year, IDEXX will sell its diagnostic products directly to U.S....
IDXX: 159.08 (+1.72)
Idexx updates guidance Q4 results
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 8:40AM CST
IDXX: 159.08 (+1.72)
IDEXX Laboratories (IDXX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Jan 30, 7:25AM CST
IDXX: 159.08 (+1.72)
Idexx tops 4Q profit forecasts
Automated Insights - Fri Jan 30, 6:40AM CST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter profit of $26 million.
IDXX: 159.08 (+1.72)
IDEXX Laboratories beats by $0.15, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 6:03AM CST
IDXX: 159.08 (+1.72)
IDEXX Laboratories Announces Fourth Quarter Results
PR Newswire - Fri Jan 30, 6:00AM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2014 of $352 million. Continued strong normalized organic revenue growth1,2 was offset in the quarter by a one-time $25 million reduction in US channel inventory related to the Company's transition to a fully-direct CAG Diagnostics sales strategy in the US and foreign exchange impacts from a stronger US dollar, resulting in a 1% reported revenue decline. Adjusting for one-time channel inventory reductions, the effect of foreign exchange rate changes, and revenue attributable to acquisitions, normalized organic revenue growth for the quarter was 9%, and 10% for the full year, supported by 11.5% normalized organic growth in CAG Diagnostics recurring revenues in Q4 and 11.4% for the full year.
IDXX: 159.08 (+1.72)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 4:30PM CST
CNX: 33.60 (+0.87), GHM: 22.84 (+0.04), SPG: 193.11 (-1.61), PCAR: 64.22 (+0.98), NS: 61.94 (-0.06), LM: 57.84 (-0.25), BZH: 17.13 (-0.04), NWL: 39.57 (+0.32), MAT: 27.61 (+0.17), MOG.A: 74.61 (+1.47), WY: 35.52 (-0.04), AVY: 53.79 (+0.14), ABBV: 58.05 (+1.00), HMC: 32.87 (+0.14), MA: 87.14 (-0.38), BERY: 34.98 (+0.03), KCG: 12.64 (-0.08), TYC: 43.19 (+0.27), INGR: 82.82 (+0.59), IMGN: 7.19 (unch), MAN: 77.51 (+0.77), IR: 67.69 (+0.06), XRX: 13.77 (+0.20), LLY: 70.56 (+0.03), TSN: 40.70 (-0.09), MO: 54.76 (-0.78), LEA: 108.70 (-0.73), NVO: 43.76 (+0.61), OFG: 17.19 (-0.31), MOSY: 2.10 (+0.02), IDXX: 159.08 (+1.72), SAIA: 45.59 (+0.98), CVX: 112.78 (+1.92), BEN: 53.91 (+0.23), MGIC: 6.40 (+0.03)
Idexx: The Growth Is There, The Moat Is There, But The Value Probably Isn't
Investing Doc - at Seeking Alpha - Tue Jan 27, 1:41PM CST
IDXX: 159.08 (+1.72), WOOF: 52.74 (-0.27), PETM: 82.70 (+0.03)
Idexx Laboratories Has Returned 34.9% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Tue Jan 27, 9:50AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 months, Idexx Laboratories has returned 34.93% as of today's recent price of $165.31.
IDXX: 159.08 (+1.72)
Meridian Bioscience: In-line Earnings, Revenue Beat in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:10AM CST
Diagnostic test-kit maker Meridian Bioscience, Inc. (VIVO) reported first-quarter fiscal 2015 (ended Dec 31, 2014) EPS of 19 cents, up 6% on a year-over-year basis and inline with the Zacks Consensus Estimate
VIVO: 19.15 (+0.16), AXDX: 22.86 (-0.33), IDXX: 159.08 (+1.72), VRML: 2.08 (+0.12)
IDEXX Laboratories to Release 2014 Fourth Quarter and Full-Year Financial Results
PR Newswire - Fri Jan 23, 2:32PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 fourth quarter and full-year financial results for Friday, January 30, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 159.08 (+1.72)
IDEXX's SDMA Test: Key to Kidney Disease Diagnosis in Pets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 12:30PM CST
IDEXX's (IDXX) SDMA test is a new renal biomarker that can detect the outset of kidney disease in cats and dogs, months or even years before traditional procedures can spot the same.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), IDXX: 159.08 (+1.72), SURG: 4.44 (-0.02)
Can Covidien (COV) Keep Its Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 10:30AM CST
The combination of Covidien's (COV) Zacks Rank #3 (Hold) and ESP of 2.91% makes us confident of an earnings beat this season.
ALGN: 56.90 (-0.34), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), IDXX: 159.08 (+1.72)
